Table 6.

Relative risks for severe and moderate exacerbation of chronic obstructive pulmonary disease comparing sodium-glucose co-transporter-2 (SGLT-2) inhibitors with sulfonylureas

	Patients	Events	Person years	Incidence rate (95% CI)* †	Crude HR or RR‡	Weighted HR or RR‡ (95% CI)†
Time to first exacerbation
Severe exacerbations:
Sulfonylureas	10 841	1006	15 740	3.9 (3.6 to 4.2)	1.00	1.00 (reference)
SGLT-2 inhibitors	2956	92	3803	2.4 (2.0 to 3.0)	0.36	0.62 (0.48 to 0.81)
Moderate exacerbations:
Sulfonylureas	10 841	704	14 860	4.3 (4.0 to 4.7)	1.00	1.00 (reference)
SGLT-2 inhibitors	2956	162	3629	4.5 (3.8 to 5.2)	0.91	1.02 (0.83 to 1.27)
No of exacerbations
Severe exacerbations:
Sulfonylureas	10 841	1586	16 816	5.4 (5.1 to 5.8)	1.00	1.00 (reference)
SGLT-2 inhibitors	2956	125	3911	3.2 (2.7 to 3.8)	0.34	0.59 (0.43 to 0.80)
Moderate exacerbations:
Sulfonylureas	10 841	1021	15 740	5.9 (5.5 to 6.3)	1.00	1.00 (reference)
SGLT-2 inhibitors	2956	224	3803	5.9 (5.2 to 6.7)	0.91	1.00 (0.79 to 1.26)

CI=confidence interval; HR=hazard ratio; RR=rate ratio.

^*Per 100 person years.

^†Weighted using propensity score fine stratification.

^‡HR for time to first exacerbation; RR for number of exacerbations.